Literature DB >> 12374982

Class IV semaphorin Sema4A enhances T-cell activation and interacts with Tim-2.

Atsushi Kumanogoh1, Satoko Marukawa, Kazuhiro Suzuki, Noriko Takegahara, Chie Watanabe, EweSeng Ch'ng, Isao Ishida, Harutoshi Fujimura, Saburo Sakoda, Kanji Yoshida, Hitoshi Kikutani.   

Abstract

Semaphorins are a family of phylogenetically conserved soluble and transmembrane proteins. Although many soluble semaphorins deliver guidance cues to migrating axons during neuronal development, some members are involved in immune responses. For example, CD100 (also known as Sema4D), a class IV transmembrane semaphorin, signals through CD72 to effect nonredundant roles in immune responses in a ligand-receptor system that is distinct from any seen previously in the nervous system. Here we report that the class IV semaphorin Sema4A, which is expressed in dendritic cells and B cells, enhances the in vitro activation and differentiation of T cells and the in vivo generation of antigen-specific T cells. Treating mice with monoclonal antibodies against Sema4A blocks the development of an experimental autoimmune encephalomyelitis that is induced by an antigenic peptide derived from myelin oligodendrocyte glycoprotein. In addition, expression cloning shows that the Sema4A receptor is Tim-2, a member of the family of T-cell immunoglobulin domain and mucin domain (Tim) proteins that is expressed on activated T cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12374982     DOI: 10.1038/nature01037

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  113 in total

Review 1.  To move or not to move? Semaphorin signalling in cell migration.

Authors:  Luca Tamagnone; Paolo M Comoglio
Journal:  EMBO Rep       Date:  2004-04       Impact factor: 8.807

2.  Dual roles of Sema6D in cardiac morphogenesis through region-specific association of its receptor, Plexin-A1, with off-track and vascular endothelial growth factor receptor type 2.

Authors:  Toshihiko Toyofuku; Hong Zhang; Atsushi Kumanogoh; Noriko Takegahara; Fumikazu Suto; Junko Kamei; Kazuhiro Aoki; Masanori Yabuki; Masatsugu Hori; Hajime Fujisawa; Hitoshi Kikutani
Journal:  Genes Dev       Date:  2004-02-20       Impact factor: 11.361

Review 3.  Regulation of immune cell responses by semaphorins and their receptors.

Authors:  Hyota Takamatsu; Tatsusada Okuno; Atsushi Kumanogoh
Journal:  Cell Mol Immunol       Date:  2010-02-01       Impact factor: 11.530

Review 4.  TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity.

Authors:  Gordon J Freeman; Jose M Casasnovas; Dale T Umetsu; Rosemarie H DeKruyff
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

5.  Neuroimmune semaphorin 4A as a drug and drug target for asthma.

Authors:  G Mogie; K Shanks; E H Nkyimbeng-Takwi; E Smith; E Davila; M M Lipsky; L J DeTolla; A D Keegan; S P Chapoval
Journal:  Int Immunopharmacol       Date:  2013-08-28       Impact factor: 4.932

6.  T cell Ig and mucin 1 (TIM-1) is expressed on in vivo-activated T cells and provides a costimulatory signal for T cell activation.

Authors:  Anjali J de Souza; Timothy B Oriss; Katherine J O'malley; Anuradha Ray; Lawrence P Kane
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-11       Impact factor: 11.205

Review 7.  Genetic characterization and disease mechanism of retinitis pigmentosa; current scenario.

Authors:  Muhammad Umar Ali; Muhammad Saif Ur Rahman; Jiang Cao; Ping Xi Yuan
Journal:  3 Biotech       Date:  2017-07-18       Impact factor: 2.406

Review 8.  The role of semaphorins in immune responses and autoimmune rheumatic diseases.

Authors:  Masayuki Nishide; Atsushi Kumanogoh
Journal:  Nat Rev Rheumatol       Date:  2017-12-07       Impact factor: 20.543

Review 9.  Semaphorin 3A: A new player in bone remodeling.

Authors:  Ren Xu
Journal:  Cell Adh Migr       Date:  2013-01-01       Impact factor: 3.405

Review 10.  Current advancements in promoting remyelination in multiple sclerosis.

Authors:  David Kremer; Rainer Akkermann; Patrick Küry; Ranjan Dutta
Journal:  Mult Scler       Date:  2018-10-01       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.